Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Rapid Commun Mass Spectrom ; 37(18): e9605, 2023 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-37580847

RESUMEN

RATIONALE: Baricitinib (BARI), an inhibitor of Janus kinases 1 and 2 (JAK 1/2), is used for the treatment of rheumatoid arthritis and COVID-19. The present study focuses on establishing the forced degradation behavior of BARI under different degradation conditions (hydrolysis, oxidation, and photolysis) following International Council for Harmonization (ICH) guidelines of Q1A (R2)-Stability testing of new drug substances and products and Q1B-Photostability testing of new drug substances and products. This study helps in monitoring the quality and safety of BARI and its product development. METHODS: Prior to conducting the study, the in silico degradation profile of BARI was predicted by Zeneth. Reversed-phase high-performance liquid chromatography employing a gradient program was used for the identification and separation of degradation impurities with an InertSustain C8 column (4.6 × 250 mm, 5 µm). The mobile phases used were 10 mM ammonium formate (pH 2.89) and acetonitrile. High-resolution mass spectrometry (HRMS) was used for the structural elucidation of the degradation impurities. RESULTS: BARI was labile to hydrolytic (acidic, basic, and neutral) and photolytic degradation conditions which yielded 10 new degradation impurities and it was stable under oxidative (H2 O2 ) conditions. The separated degradation impurities were characterized by HRMS and the respective degradation pathways were proposed. The generated information helped to propose a mechanism for the formation of the degradation impurities. Additionally, one-dimensional and two-dimensional nuclear magnetic resonance spectroscopy were used for the characterization of two major degradation impurities. CONCLUSION: The forced degradation study of BARI was carried out in accordance with ICH Q1A and Q1B guidelines, which resulted in the formation of 10 new degradation impurities. In our analysis, three degradation impurities were matching with the Zeneth predictions. In silico tools, DEREK Nexus® and SARAH Nexus®, were used for predicting the toxicity and mutagenicity of BARI and its degradation impurities. Overall, this study sheds light on BARI's safety monitoring and storage circumstances.


Asunto(s)
COVID-19 , Espectrometría de Masas en Tándem , Humanos , Espectrometría de Masas en Tándem/métodos , Cromatografía Líquida de Alta Presión/métodos , Tratamiento Farmacológico de COVID-19 , Oxidación-Reducción , Espectroscopía de Resonancia Magnética/métodos , Hidrólisis , Fotólisis , Estabilidad de Medicamentos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...